Jazz Pharmaceuticals plc (NASDAQ:JAZZ) ranks among the mid-cap stocks to buy according to top investors. Truist Securities increased its price target for Jazz Pharmaceuticals plc (NASDAQ:JAZZ) to $230 from $220 on January 12, preserving a Buy rating on the company. The rise follows practice-changing results from the HERIZON-GEA trial, which Truist used to justify adjusting its Ziihera estimations higher.
In order to get a broad label for first-line gastroesophageal adenocarcinoma (GEA) as both doublet and triplet therapy with priority review, Jazz Pharmaceuticals plc (NASDAQ:JAZZ) executives intends to file a supplemental Biologics License Application (sBLA) in the initial half of 2026.
After clearance based on clinical data, Truist Securities anticipates strong commercial adoption, probable adoption in NCCN guidelines, over 90% prescriber crossover between GEA and biliary tract cancer (BTC), and compatibility of PD-1 inhibitor selection.
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is a biopharmaceutical company that develops treatments for serious illnesses. Its key products include Xywav, Xyrem, Epidiolex, Rylaze, Zepzelca, Defitelio, and Vyxeos.
READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.
This article is originally published at Insider Monkey.
